Haemonetics - HAE Stock Forecast, Price & News

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Haemonetics Stock Performance

NYSE:HAE traded up $2.13 on Friday, hitting $75.20. 345,863 shares of the company's stock traded hands, compared to its average volume of 394,326. The company has a current ratio of 3.81, a quick ratio of 1.05 and a debt-to-equity ratio of 0.99. The firm's 50-day moving average price is $65.98 and its two-hundred day moving average price is $59.72. Haemonetics has a 1-year low of $43.50 and a 1-year high of $77.08. The firm has a market capitalization of $3.86 billion, a PE ratio of 57.41 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Rating) last posted its earnings results on Wednesday, August 10th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.07. Haemonetics had a net margin of 6.60% and a return on equity of 18.62%. The firm had revenue of $261.50 million during the quarter, compared to analysts' expectations of $249.00 million. During the same period in the previous year, the business posted $0.50 EPS. The business's revenue was up 14.4% compared to the same quarter last year. As a group, analysts expect that Haemonetics will post 2.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HAE. Barrington Research boosted their target price on shares of Haemonetics from $77.00 to $88.00 and gave the stock an "outperform" rating in a research report on Thursday. JMP Securities boosted their target price on shares of Haemonetics from $80.00 to $90.00 and gave the stock a "market outperform" rating in a research report on Thursday. Morgan Stanley boosted their target price on shares of Haemonetics from $70.00 to $74.00 and gave the stock an "equal weight" rating in a research report on Thursday. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a research note on Thursday, July 21st. Finally, Raymond James lifted their price objective on shares of Haemonetics from $76.00 to $88.00 and gave the company an "outperform" rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $79.80.

Insider Activity at Haemonetics

In related news, CEO Christopher Simon sold 1,148 shares of the business's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $62.60, for a total value of $71,864.80. Following the completion of the transaction, the chief executive officer now directly owns 213,724 shares in the company, valued at approximately $13,379,122.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Christopher Simon sold 1,148 shares of the business's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $62.60, for a total value of $71,864.80. Following the completion of the sale, the chief executive officer now owns 213,724 shares of the company's stock, valued at approximately $13,379,122.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Josep Llorens sold 1,418 shares of the business's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $59.10, for a total transaction of $83,803.80. Following the completion of the sale, the executive vice president now directly owns 17,335 shares of the company's stock, valued at approximately $1,024,498.50. The disclosure for this sale can be found here. Insiders sold a total of 8,095 shares of company stock worth $482,496 in the last three months. Company insiders own 1.65% of the company's stock.